Kailera Therapeutics Raises $600 Million
Kailera Therapeutics, an obesity drug startup, has secured $600 million in funding from investors.
The financing round, led by Bain Capital's private equity group, also included investments from Royalty Pharma and sovereign wealth funds in Canada and Qatar.
- Several of Kailera's founding investors also contributed to the funding.
- The deal highlights the ongoing interest in weight loss drugs despite past clinical disappointments.
This Series B round comes almost exactly one year after the startup launched with $400 million and follows Pfizer's announcement to acquire Metsera, another obesity drug developer, for $4.9 billion.
No direct quote available in the text.
Author's summary: Kailera Therapeutics raises $600 million in funding.